Alefacept, a CD2-binding leukocyte-function associated antigen (LFA)-3 Ig fusion protein has been proposed to clear psoriasis lesions through the depletion of CD2-expressing cells [147], which includes T cells but also DCs, although to low level. This evidence concerns the gene CD2 and psoriasis.